
Altimmune fell 70.1% from $4.65 to $1.39, behind the S&P 500's +10.6%. Its worst day was Dec 19 (−22.8%), and its low came Nov 18 at $1.39.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepointAdditional weight loss from 24 to 48 weeks with 1.8 mg dose,
−22.8%, the year's worst day · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
Altimmune shares rose 16.5%, while the S&P 500 rose 0.7%.
+16.5%, the year's best day · S&P 500 +0.7%
Altimmune closed at its highest level of the year, 32.9% above where the year started.
+9.2% · S&P 500 +0.4%
EPS of $-0.27 missed the $-0.25 estimate on $26,000.00 revenue (est. $560.00).
−17.9% · S&P 500 −0.6%
Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and general corporate
−16.7%, on 30M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $-0.18 beat the $-0.25 estimate on $0.00 revenue (est. $1,000.00).
−1.9% · S&P 500 +0.6%
EPS of $-0.12 beat the $-0.13 estimate on $0.00 revenue (est. $1,400.00).
−2.3% · S&P 500 +0.3%
EPS of $-0.15 missed the $-0.14 estimate on $0.00 revenue (est. $1,400.00).
−16.6% · S&P 500 −0.4%
Where it ended: a close of $1.39 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.17).
Nothing in the past 12 months.
All ALT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALT and SPY from Benzinga historical bars. Not investment advice.